Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like this transaction insofar as ZBH got full market value for its ZIMV shares.
ZBH divested its_equity_stake_in ZIMV spin-off in cashless swap of equity for debt:
https://www.sec.gov/Archives/edgar/data/1136869/000106299323002100/xslF345X03/form4.xml
ZBH reports 4Q22 results—issues 2023 guidance:
https://finance.yahoo.com/news/zimmer-biomet-announces-fourth-quarter-113000895.html
2023 non-GAAP EPS guidance is $6.95-7.15, which is 1-4% growth vs 2022 non-GAAP EPS of $6.89.
ZBH makes small acquisition in tissue healing:
https://finance.yahoo.com/news/zimmer-biomet-acquire-embody-inc-120000718.html
Electromagnetic field induced biological effects in humans
Dr. Lal was working on a ceramic coating before joining ZBH in 2018. Maybe he is in Swindon? In addition to reducing the EM amplification effect, ceramic coatings also reduce the amount of titanium in the blood by reducing corrosion. But again the coating needs to be the right ceramic thats more biologically compatible. Dr. Lal was working with one such substance when he was involved with Life Long Joints projects.
Are there hip and knee implants with ceramic coatings? I thought it was just articulating surfaces? Also some ceramics are better than others. ZTA is somewhat toxic and inflammatory.
Using the term radio signal doesn't accurately convey that those radio signals are sources of electromagnetic radiation. While I know its easier to believe these sources of radiation and accompanying metal implants are not causing problems but there are case studies showing it.
Yes companies like ZBH are in trouble if they dont adopt a ceramic coating which significantly reduces the aforementioned effect.
Consider the source! If radio signals were so clearly a major health concern for those with metal implants, as suggested in your cited article, orthopedics companies like ZBH would be in very big trouble.
p.s. I highly doubt that radio signals from cellphones are a material contributor to COVID morbidity and mortality.
Evidence for a connection between coronavirus disease-19 and exposure to radiofrequency radiation from wireless communications including 5G
Titanium exposure and human health
Health issue which is quite numerous in the ways that EM radiation and metal implants cause issues. Even play into covid severity.
I know technology seems like its making things better but its a double edge sword.
Are you talking about a health issue... or about interference of the radio signal?
And what about the radiation emitted by the watch and amplified by the metal implant?
I'm not saying the watch is bad by itself but its just yet another device emitted EM radiation but in the case of a watch, near one of the largest metal implants. Of course a ceramic coating can reduce the amplification.
ZBH has a collaboration with Apple Watch that improves post-surgical patient care and generates incremental margins on ZBH’s orthopedics sales:
https://finance.yahoo.com/news/zimmer-biomet-announces-one-data-120000697.html
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2022 Earnings Call Transcript
https://seekingalpha.com/article/4552093-zimmer-biomet-holdings-inc-zbh-q3-2022-earnings-call-transcript
ZBH 3Q22 results:
https://finance.yahoo.com/news/zimmer-biomet-announces-third-quarter-103000416.html
3Q22 sales were -1% YoY in dollars, but +5% YoY in constant currency.
2022 non-GAAP EPS guidance is now $6.80-6.90 (from the prior range of $6.70-6.90).
Zimmer Biomet Q2 2022 Earnings Call Transcript
https://www.marketbeat.com/earnings/transcripts/76883/
ZBH 2Q22 results—2022 guidance:
https://finance.yahoo.com/news/zimmer-biomet-announces-second-quarter-103000502.html
2022 non-GAAP EPS guidance from continuing operations has been raised slightly to $6.70-6.90 (from prior range of $6.6.65-6.85).
ZBH 1Q22 results—2022 guidance:
https://investor.zimmerbiomet.com/news-and-events/news/2022/05-03-2022-113116507
1Q22 sales were +7% YoY in constant currency. 1Q22 non-GAAP EPS was $1.61, excluding the from the ZIMV segment during Jan and Feb, prior to the 3/1/22 spin-off. This compares to $1.71 non-GAAP EPS in 1Q21 (which included the ZIMV segment).
Elective-procedure recovery was stronger than the company expected. In Mar 2022 (but not Jan and Feb), procedure volume was higher than 2019 (pre-pandemic) levels.
2022 non-GAAP EPS guidance was raised and tightened to $6.65-$6.85 (from the prior range of $6.40-6.80).
ZBH is now trading ex-spinoff of ZIMV.
Zimmer Biomet Holdings Inc. (ZBH) CEO Bryan Hanson on Q4 2021 Results - Earnings Call Transcript
https://www.google.com/amp/s/seekingalpha.com/amp/article/4484960-zimmer-biomet-holdings-inc-zbh-ceo-bryan-hanson-on-q4-2021-results-earnings-call-transcript
other analyst from earlier today
JMP Market Outperform from $175 to $145
Truist Buy from $145 to $128
RBC Sector Perform from $140 to $125
Wells Fargo maintains underweight lowers target to $111
Deutsche Bank maintains hold, lowers target to $121
$ZBH Needham analyst Mike Matson maintains Zimmer Biomet Holdings with a Buy and lowers the price target from $155 to $143
$ZBH SVB Leerink analyst Danielle Antalffy maintains Zimmer Biomet Holdings with a Outperform and lowers the price target from $150 to $135
$ZBH Canaccord Genuity analyst Kyle Rose downgrades Zimmer Biomet Holdings from Buy to Hold and lowers the price target from $165 to $125
$ZBH Piper Sandler from $135.00 to $110.00
2/7 Monday's close 111.67
It's unclear with just headline analyst target's if it includes ZimVie or without ZimVie
to repeat
Zimmer Biomet shareholders of record as of the close of business on February 15, 2022 (the "Record Date"). The dividend is payable at 12:01 a.m. ET on March 1, 2022 (the "Distribution Date"). As a result of the dividend, Zimmer Biomet shareholders will receive one share of ZimVie common stock for every ten shares of Zimmer Biomet common stock they hold on the Record Date.
This is ZBH’s biggest biz-dev transaction since the merger of Zimmer and Biomet in 2015.
ZIMV 2022 non-GAAP EPS guidance=$2.10-2.30:
https://finance.yahoo.com/news/zimvie-hosts-inaugural-investor-day-141500225.html
ZBH -7% because of soft 2022 guidance announced with 4Q21 results:
https://finance.yahoo.com/news/zimmer-biomet-announces-fourth-quarter-113000363.html
ZBH PR/slides re ZimVie (ZIMV) spinoff:
https://www.prnewswire.com/news-releases/zimmer-biomet-announces-expected-completion-date-of-march-1-2022-for-spinoff-of-zimvie-301476209.html
https://78449.choruscall.com/dataconf/productusers/zbh/media/2022/zbh220207_1100_presentation.pdf
Zimmer Biomet Holdings Inc (ZBH) Q3 2021 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2021/11/04/zimmer-biomet-holdings-inc-zbh-q3-2021-earnings-ca/
Zimmer Biomet Holdings Inc (ZBH) Q2 2021 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2021/08/03/zimmer-biomet-holdings-inc-zbh-q2-2021-earnings-ca/
Someones gotta post this.
ZBH 2Q21 sales_flat–to-slightly-down_vs_2Q19—(way up vs pandemic 2Q20):
https://finance.yahoo.com/news/zimmer-biomet-announces-second-quarter-103000408.html
Updated 2021 full-year non-GAAP EPS guidance is $7.65-7.95 (narrowed from $7.60-8.00).
Zimmer Biomet Holdings Inc (ZBH) Q1 2021 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2021/05/04/zimmer-biomet-holdings-inc-zbh-q1-2021-earnings-ca/
ZBH issues_2021_guidance—>12.5-15.5%_YoY_revenue_growth_in_constant_currency:
https://investor.zimmerbiomet.com/~/media/Files/Z/ZimmerBiomet-IR/press-release/q1-2021-earnings-release.pdf
Zimmer Biomet Holdings Inc (ZBH) Q4 2020 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2021/02/05/zimmer-biomet-holdings-inc-zbh-q4-2020-earnings-ca/
The stock is +5% in PM trading. Investors are suckers for spin-offs.
ZBH to spin-off dental/spine businesses—(two losers):
https://finance.yahoo.com/news/zimmer-biomet-announces-intent-spin-113100667.html
The spin-off company has yet to be named. Deal closing is targeted for mid-2022. The deal is tax-free for ZBH shareholders.
ZBH 4Q20 results—no 2021 guidance due to COVID:
https://investor.zimmerbiomet.com/news-and-events/news/2021/02-05-2021-113032509
Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q3 2020 Results - Earnings Call Transcript
https://www.google.com/amp/s/seekingalpha.com/amp/article/4386109-zimmer-biomet-holdings-inc-zbh-ceo-bryan-hanson-on-q3-2020-results-earnings-call-transcript
ZBH_3Q20_results—no_4Q20_guidance_due_to_COVID:
https://finance.yahoo.com/m/62919b99-2139-3ee7-a0dd-02f484b7d7ec/3-reasons-pfizer-s-imminent.html
Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q2 2020 Results - Earnings Call Transcript
https://seekingalpha.com/article/4364273-zimmer-biomet-holdings-inc-zbh-ceo-bryan-hanson-on-q2-2020-results-earnings-call-transcript
ZBH—(-4%)—declines to reinstate 2020 guidance (which was withdrawn on 4/6/20):
https://investor.zimmerbiomet.com/~/media/Files/Z/ZimmerBiomet-IR/press-release/q1-2020-earnings-release.pdf
ZBH quantifies the damage—in part:
https://www.prnewswire.com/news-releases/zimmer-biomet-provides-update-on-covid-19-impact-301036176.html
Followers
|
6
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
126
|
Created
|
08/11/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |